Peregrine Asset Advisers’s AstraZeneca AZN Stock Holding History

Peregrine Asset Advisers’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$465K	Hold	2,450	–	–	0.1%	142
2026 Q1	$483K	Hold	2,450	–	–	0.13%	122
2025 Q4	$450K	Hold	2,450	–	–	0.13%	112
2025 Q3	$376K	Hold	2,450	–	–	0.11%	126
2025 Q2	$342K	Hold	2,450	–	–	0.11%	128
2025 Q1	$360K	Hold	2,450	–	–	0.13%	115
2024 Q4	$321K	Sell	2,450 -16	-0.6%	-$2.24K	0.12%	118
2024 Q3	$384K	Hold	2,466	–	–	0.13%	121
2024 Q2	$385K	Hold	2,466	–	–	0.15%	109
2024 Q1	$334K	Hold	2,466	–	–	0.13%	118
2023 Q4	$332K	Hold	2,466	–	–	0.16%	111
2023 Q3	$334K	Buy	+2,466	New	+$337K	0.17%	106
2022 Q2	–	Sell	-1,600	Closed	-$212K	–	81
2022 Q1	$212K	Buy	+1,600	New	+$192K	0.11%	104
2020 Q2	–	Sell	-1,600	Closed	-$143K	–	98
2020 Q1	$143K	Buy	+1,600	New	+$151K	0.11%	97

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Peregrine Asset Advisers's AZN Position: Q2 2026 in Review

Peregrine Asset Advisers held its AstraZeneca (AZN) position steady in Q2 2026 at 2,450 shares worth $465K. The position accounts for 0.1% of the portfolio, ranked #142.

Peregrine Asset Advisers first reported a position in AZN in Q1 2020 and has held it in 14 quarters since. The position peaked at $483K in Q1 2026. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Peregrine Asset Advisers held 2,450 shares of AstraZeneca worth $465K as of Q2 2026.
Peregrine Asset Advisers left its AstraZeneca share count unchanged in Q2 2026.
AstraZeneca made up 0.1% of Peregrine Asset Advisers's portfolio in Q2 2026, its #142 holding.
Peregrine Asset Advisers first reported a position in AstraZeneca in Q1 2020 and has held it in 14 quarters since.
Peregrine Asset Advisers's AstraZeneca position peaked at $483K in Q1 2026.
1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Peregrine Asset Advisers's 13F filing for Q2 2026, filed 10 Aug 2026.